3PBIOVIAN Revenue and Competitors
Estimated Revenue & Valuation
- 3PBIOVIAN's estimated annual revenue is currently $97.1M per year.
- 3PBIOVIAN's estimated revenue per employee is $243,316
Employee Data
- 3PBIOVIAN has 399 Employees.
- 3PBIOVIAN grew their employee count by 523% last year.
3PBIOVIAN's People
Name | Title | Email/Phone |
---|---|---|
1 | Manager, Support Functions | Reveal Email/Phone |
3PBIOVIAN Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $26.3M | 131 | 49% | N/A | N/A |
#2 | $108.1M | 538 | 9% | N/A | N/A |
#3 | $39.2M | 195 | 25% | N/A | N/A |
#4 | $42.4M | 211 | -5% | N/A | N/A |
#5 | $126.1M | 448 | 17% | $446.2M | N/A |
#6 | $69.3M | 345 | 28% | N/A | N/A |
#7 | $60.1M | 299 | 53% | N/A | N/A |
#8 | $26.5M | 132 | -1% | N/A | N/A |
#9 | $20.1M | 100 | 22% | N/A | N/A |
#10 | $32.4M | 161 | 26% | N/A | N/A |
What Is 3PBIOVIAN?
3PBIOVIAN service offering includes microbial and mammalian protein expression platforms, viral vector production for adenoviruses and adeno-associated viruses, cell therapy, and plasmid DNA production, with the provision for fill and finish services for recombinant proteins and viral vectors. Leveraging a combined track record of 40 years in process development and analytical methods development, complemented by the experience in process scale-up, GMP manufacturing, and commercial supply, 3PBIOVIAN is equipped to offer comprehensive manufacturing services at all stages, encompassing Drug Substance and Drug Product. Manufacturing sites in Pamplona-Noáin, Spain, and Turku, Finland seamlessly support the diverse needs of clients, covering pre-clinical and clinical supply to full-scale commercial manufacturing.
keywords:N/AN/A
Total Funding
399
Number of Employees
$97.1M
Revenue (est)
523%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $116.3M | 403 | -7% | N/A |
#2 | $114.6M | 404 | 16% | N/A |
#3 | $137.4M | 407 | 42% | N/A |
#4 | $138.4M | 410 | 52% | N/A |
#5 | $68.2M | 413 | 28% | $150.2M |